You are here

Research

The Cantley lab employs a wide range of techniques in its investigation of cancer metabolism and phosphoinositide signaling

Last Updated: March 25, 2015

The vast majority of pancreatic ductal adenocarcinomas (PDAC) involve activating mutations in KRAS (KRAS*) and as with other KRAS* cancers, PDAC show minimal response to existing therapies used in the clinic. While no satisfactory KRAS*-specific drugs are currently available, inhibitors of MEK and PI3K (MEKi and PI3Ki) pathways necessary for KRAS*-mediated cellular transformation in vitro are now being introduced into clinical trials. Read more.

Last Updated: March 25, 2015

Loss of function mutations in STK11, encoding the Ser/Thr protein kinase, LKB1 are responsible for the familial hamartoma syndrome, Peutz Jeghers Syndrome (PJS). Importantly, recent studies have revealed sporatic mutations in STK11 in a variety of human cancers, including lung adenocarcinomas. LKB1 phosphorylates and activates AMP dependent protein kinase in response to energy stress, and thus plays a key role in energy homeostasis. Read more.

Last Updated: March 25, 2015

Impairments in the ability of insulin to stimulate PI3K in liver and muscle results in insulin resistance and type 2 diabetes, while genetic aberrations that result in hyper-activation of PI3K in epithelial tissues results in cancers. Activating mutations in PIK3CA, the gene encoding the p110 [unreadable] catalytic subunit of PI3K, are among the most frequent oncogenic occurrences in epithelial cancers. Read more.

Last Updated: March 25, 2015

The protein NRF2 is a transcription factor, which means that its role is to regulate expression of specific genes within a cell. Among other functions, NRF2 has been shown to be involved in metabolic pathways in the cell, in which nutrients are broken down to provide energy for cellular functions Read more.

Contact Us

Meyer Cancer Center
Belfer Research Building
413 E 69th St.
Room 1362, Box 50
New York, NY 10021
Phone: (646) 962-6297